CMS' Slavitt: Business practices have to change

“It’s not technology that’s holding us back. It’s business practice,” said Andy Slavitt, acting administrator of the Centers for Medicare & Medicaid Services (CMS), speaking at the Bipartisan Policy Center’s program on interoperability.

CMS’ commitment to having more than half of payments come from alternative payment models by 2018 means a tipping point is in sight. That gives physicians and others a reason other than incentives to want the technology, “because they need to connect and care for the patient. We cannot get there without information. The hope is we spend less time talking about how to manage and manipulate technology and more time talking to physicians about what they care about and how to support that. We want to get away from micromanaging every step of how someone uses technology.”

The federal government can do everything within its power but people still have to change the way they practice, he said. Until that happens there won’t be any progress but once that happens, “we’ll make fast progress.”

The government’s role is to level the playing field, Slavitt said. The reasoning behind open APIs is so that no one company has a lock on the physician workflow. Open APIs will get healthcare away from dominance of the field by a few players.

Another lever the government uses, he said, is incentives but that is changing as well. “I’m more interested in incentives that reward physicians for coordinating care…not rewarding people for the mode but for achieving the means.”

Slavitt talked about meeting with about one dozen hospital CEOs to talk about the Shared Savings Program, a form of an accountable care organization. The CEOs provided feedback and one said that if the rules weren’t changed in several ways, he would leave the program. “We’re going to be in sad shape if people wait for CMS to set up the perfect system to make them do the right thing. I will gladly reward physicians and hospitals but I can’t do it for them. Nobody wants the federal government to play that role.”

When Slavitt came into his position, he said, there was a goal to speak with a clearer voice. “We don’t want to make people decipher our regulations to figure out what’s important. Technology and interoperability are really important and there’s a moral component to the issue.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.